Serum Neuroglobin and HIF-1α in Acute Ischemic Stroke

Completed

• Conditions: Acute Ischemic Stroke

• Registration Number: NCT02297984
• Lead Sponsor: Shanghai 6th People's Hospital

Brief Summary

Neuroglobin has shown rich neuroprotective effects against cerebral ischemia and hypoxia, and therefore has the potential to impact outcomes after acute ischemic stroke. Hypoxia inducible factor (HIF)-1α is neuroprotective in several models of experimental brain injury and is increased in brain after acute cerebral infarction in humans and experimental animals.The investigators sought to examine the changes in serum neuroglobin and HIF-1α concentrations in patients with acute ischemic stroke during the initial 96-h period after stroke and assessed the relation between them and the relation of them to prognosis of such patients with acute ischemic stroke.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-10
• Primary Completion: 2014-09
• Study Completion: 2014-10
• Study First Submitted: 2014-11-19
• Study First Submitted QC: 2014-11-20
• Study First Posted: 2014-11-21
• Status Verified: 2020-08
• Last Update Submitted: 2020-08-08
• Last Update Posted: 2020-08-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Clinical diagnosis of acute ischemic stroke
• Admission within 12 hours

Exclusion Criteria

• Lacunar infarction
• Cerebral hemorrhagic infarction
• Epilepsy or epileptic persons
• History of neurological diseases, myocardial infarction, renal and hepatic abnormalities and metabolic diseases
• Contraindications to antiplatelet treatments
• Serial blood samples could not be obtained

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Modified Rankin Scale scores	3 months	0 = No symptoms; 1 = No significant disability. Able to carry out all usual activities, despite some symptoms; 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 = Moderate disability. Requires some help, but able to walk unassisted; 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 = Dead.

Secondary Outcome Measures

Name	Time	Method
Glasgow Outcome Scale scores	3 months	Glasgow Outcome Scale 1 = death; Glasgow Outcome Scale 2 = vegetative state; Glasgow Outcome Scale 3 = severe neurological deficit; Glasgow Outcome Scale 4 = mild neurological deficit and Glasgow Outcome Scale 5 = premorbid level of functioning or completely recovery.

Trial Locations

Locations (1)

Shanghai Sixth People's Hospital; 🇨🇳 Shanghai, China